ZIM LABORATORIES LIMITED

Zim Laboratories Limited held its Q1 FY27 Earnings Conference Call on August 7, 2026, where management provided updates on the EU-GMP remediation process, which remains a strategic priority. The inspection by regulatory authorities was completed, and management is awaiting the final report. They reported a total operating income of approximately INR 942 million, reflecting a 31.2% year-over-year growth, although EBITDA margins were impacted by planned investments. Exports contributed about 84% of total income, and the innovative product portfolio accounted for approximately 18% of revenue. Management highlighted the importance of completing the EU-GMP process to unlock growth opportunities and expressed confidence in the company's positioning for future growth. The call included a Q&A session where management addressed questions regarding expenses, debt levels, and the impact of geopolitical uncertainties on business performance.

Management provided a balanced overview of performance and challenges without strong emphasis on either growth or headwinds.